Investors
Stock Quote
ICCC Stock Price
Data provided by Yahoo Finance. Prices may be delayed. Not financial advice.
Press Releases
Recent News | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014
SEC Filings
SEC Filings
Annual Report and Proxy
Corporate
Governance
ICCC Code of Conduct
Charter and Powers of the Audit Committee
Nominating Committee Charter
Management & Directors
2023 Press Releases
11-13-23 ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023
11-7-23 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023
10-5-23 ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023
08-29-23 ImmuCell Announces Submission of CMC Technical Section to the FDA
08-10-23 ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023
08-07-23 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023
07-11-23 ImmuCell Announces Preliminary, Unaudited Sales Results Q2 2023
06-28-23 ImmuCell Announces Change in Timing of Anticipated FDA Submission
06-21-23 ImmuCell Appoints Bryan K. Gathagan to Board of Directors
06-15-23 ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility
05-16-23 ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
05-11-23 ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023
05-04-23 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023
04-05-23 ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023
02-21-23 ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022
02-15-23 ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022
Company Contact
Olivier te Boekhorst
President & CEO
investor.relations@immucell.com
Investor Contact
Lytham Partners, LLC
iccc@lythampartners.com
602.889.9700